Innovator Awards for Posthemorrhagic Hydrocephalus
The Hydrocephalus Association is soliciting applications for research on posthemorrhagic hydrocephalus. The goal of this initiative is to provide seed funding for bold and innovative research with the potential to transform the field of hydrocephalus through the understanding of disease mechanisms and the development of novel therapies and treatment approaches. This award is not intended to support human trials nor is it intended to support the development of new animal, ex vivo, or in vitro models of hydrocephalus for the purpose of future research.
The award provides short term seed funding for up to 12 months. Proposals may be submitted for actual costs at one of two funding levels, $25,000 or $50,000. Total funding through this RFA is expected to be $200,000. The number of awards made will depend on the quality of the applications received and the research priorities determined by the Hydrocephalus Association. The Hydrocephalus Association will accept applications from researchers based at accredited non-profit research and academic institutions throughout the world. The award provides no institutional overhead. All applications must be submitted in English. In upcoming years, the Hydrocephalus Association anticipates a follow-on RFA for multiyear support.
This award is not open to current Innovator Award grantees.
To be eligible, candidates must:
- Have a publication record containing articles that are innovative and high impact
- Have demonstrated the ability to independently supervise staff and research
- Have completed one or more of the following degrees: MD, PhD, DSc, DO, Pharm.D, or equivalent
- Hold a research associate, assistant professorship, associate professorship, professorship, or any equivalent academic or non-academic position
Applicants must sign up through the Hydrocephalus Association’s Network for Discovery Science to apply. To create a HANDS account and submit your application, please visit: http://hands.hydroassoc.org/.
The Letter of Intent (LOI) components include:
Click HERE for LOI FORM
- A one-page summary of the project
- Identification of the supporting institution
- Identification of three potential reviewers
The Full Application components include:
- Contact details and other relevant administrative information (Face Page)
- Proposal Budget (Budget)
- Biographical sketches are required for the Applicant, Co-Investigator (if applicable), and Key Personnel. Biographical Sketches should not to exceed four (4) pages (BioSketch)
- A research plan for the proposed project, of not more than five (5) pages, that contains a summary, specific aims and hypotheses, background and significance, research design and methods, next steps, and literature cited. (Research Plan)
- Describe institutional facilities and any consultations/collaborations if applicable. (Facilities and Collaborations)
- Applications from all candidates should also include a letter from the appropriate administrative institutional official confirming the institutions commitment to the responsible conduct of research, the candidate’s eligibility and good standing, and that, if selected, the candidate would be able to accept the award.
All applicants must provide assurance of compliance with local research regulatory bodies and with local laws in advance of the award start date. Additionally, for applications using human embryonic stem cells or human tissue the candidate must obtain appropriate Embryonic Stem Cell Research Oversight Committee (ESCRO) and human subjects research approvals in advance of the award start date.
All applicants must submit an LOI. LOIs must be submitted in the online system before 5:00 PM (Eastern) on September 1, 2016. LOI decisions and invitations to submit full proposals will be made by mid-September. Full applications are due before 5:00 PM (Eastern) on November 3, 2016. Grant finalists will be contacted in December 2016 and announced in January 2017. For additional information, please contact Jenna Koschnitzky, PhD at email@example.com or 240.483.4540.